<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01720667</url>
  </required_header>
  <id_info>
    <org_study_id>NoGA - R01 FD004147-01A1 Haas</org_study_id>
    <secondary_id>1R01FD004147-01A1</secondary_id>
    <nct_id>NCT01720667</nct_id>
  </id_info>
  <brief_title>Efficacy of Intravenous Levetiracetam in Neonatal Seizures</brief_title>
  <acronym>NEOLEV2</acronym>
  <official_title>Efficacy of Intravenous Levetiracetam in Neonatal Seizures: A Phase 2 Randomized Blinded Controlled Study of the Efficacy of Intravenous Levetiracetam (LEV) as First Line Treatment for Neonatal Seizures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Richard H. Haas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rady Children's Hospital, San Diego</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Auckland City Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sharp Mary Birch Hospital for Women &amp; Newborns, San Diego, CA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>UCSF Benioff Children's Hospital Oakland, Oakland, CA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Diego</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A new anticonvulsant, levetiracetam will be studied to treat seizures in newborn infants.
      Current treatments for the brain damaging complication of neonatal seizures are
      unsatisfactory.

      Monitoring for seizure detection will be tested at five (5) US sites and one (1)
      international site using the internet.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This project aims to improve the treatment of neonatal seizures. Current treatments are
      poorly effective and have significant side effects.

      Levetiracetam (LEV) has great potential as a treatment for neonatal seizures but is not
      approved for use in children less than 2 years of age.

      This study aims to obtain essential data regarding the efficacy and safety of LEV in this
      vulnerable and under researched population and simultaneously to develop EEG monitoring
      systems that facilitate seizure detection and research.

      Specific aims are:

        1. To determine the efficacy of intravenous LEV in terminating neonatal seizures when given
           as first line therapy.

        2. To obtain dose escalation data by studying the additional efficacy of a further dose in
           non responders.

        3. To obtain additional pharmacokinetic data to confirm findings from our previous
           pharmacokinetic study.

        4. To obtain further safety data of LEV in neonates.

        5. To prove the feasibility of centralized remote monitoring of continuous EEG monitoring
           in the Neonatal Intensive Care Unit (NICU) via the internet and test a promising
           automated neonatal seizure detection algorithm.

      The study design is a phase 2 randomized blinded controlled study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">September 2017</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the efficacy of intravenous LEV in terminating neonatal seizures when given as first line therapy compared to phenobarbital</measure>
    <time_frame>48 hours</time_frame>
    <description>A head to head comparison of the efficacy of intravenous levetiracetam versus phenobarbital in the treatment of EEG proven neonatal seizures. Seizure burden will be assessed by duration and frequency of seizure events.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To obtain dose escalation data by studying the additional efficacy of a further dose in non responders.</measure>
    <time_frame>48 hours</time_frame>
    <description>Determine the efficacy of higher dose levetiracetam compared to phenobarbital in reducing seizure burden.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the benefit of remote EEG monitoring</measure>
    <time_frame>48 hours</time_frame>
    <description>To prove the feasibility of centralized remote monitoring of continuous EEG monitoring in the NICU via the internet by documentation of remote accessibility of EEG recordings.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the accuracy of neonatal seizure detection algorithm</measure>
    <time_frame>48 Hours</time_frame>
    <description>A novel neonatal seizure detection algorithm will be compared to the gold standard of two encephalographers reading 48 hours of neonatal video EEG in the measurement of seizure burden.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Pharmacokinetic Data</measure>
    <time_frame>48 hours</time_frame>
    <description>To obtain additional pharmacokinetic data &quot;Area under the plasma concentration versus time curve (AUC) and Peak Plasma Concentration (Cmax)&quot; of intravenous levetiracetam to confirm findings from our previous pharmacokinetic study.</description>
  </other_outcome>
  <other_outcome>
    <measure>Gather safety information on IV levetiracetam</measure>
    <time_frame>48 Hours</time_frame>
    <description>Safety information to be collected includes any adverse events and blood parameter monitoring with Complete Blood Count and Comprehensive Chemistry panels after 48 hours of treatment.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Neonatal Seizures</condition>
  <arm_group>
    <arm_group_label>Intravenous levetiracetam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous levetiracetam 40 to 60 mg/kg loading dose. 10 mg/kg 8 hourly maintenance</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intravenous phenobarbital</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravenous phenobarbital 20 to 40 mg/kg load. 1.5 mg/kg 8 hourly maintenance</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous levetiracetam</intervention_name>
    <description>Intravenous load of levetiracetam (40 to 60 mg/kg) following identification of EEG confirmed neonatal seizure.</description>
    <arm_group_label>Intravenous levetiracetam</arm_group_label>
    <other_name>Keppra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous phenobarbital</intervention_name>
    <description>Intravenous load of phenobarbital (20 to 40 mg/kg)following EEG confirmation of seizure activity load.</description>
    <arm_group_label>Intravenous phenobarbital</arm_group_label>
    <other_name>phenobarbitone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Newborns admitted to any of the study sites with electrographic seizures seizures.

          2. Term infants gestational age &gt;36 weeks less than 2 weeks of age.

          3. Greater than 2200 grams.

          4. Infants for whom parental consent to participate in the study is obtained.

        Exclusion Criteria:

          1. Infants who are already receiving anticonvulsants

          2. If serum creatinine is greater than 1.6mM

          3. If seizures are due to correctable metabolic abnormalities (i.e. hypoglycaemia,
             hypocalcemia, hyponatremia)

          4. Subjects in whom death seems imminent, as assessed by the neonatologist.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>14 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard H Haas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Diego</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Richard H Haas, MD</last_name>
    <phone>858-966-5819</phone>
    <email>rhaas@ucsd.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gail E Reiner, DNP, FNP-C</last_name>
    <phone>858-966-5819</phone>
    <email>gereiner@ucsd.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of California, San Diego Medical Center / Neonatal Intensive Care Unit (NICU)</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard H Haas, MD</last_name>
      <phone>858-822-6700</phone>
      <email>rhaas@ucsd.edu</email>
    </contact>
    <contact_backup>
      <last_name>Gail E Reiner, DNP, FNP-C</last_name>
      <phone>619-471-9134</phone>
      <email>gereiner@ucsd.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Richard H Haas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Sharpe CM, Capparelli EV, Mower A, Farrell MJ, Soldin SJ, Haas RH. A seven-day study of the pharmacokinetics of intravenous levetiracetam in neonates: marked changes in pharmacokinetics occur during the first week of life. Pediatr Res. 2012 Jul;72(1):43-9. doi: 10.1038/pr.2012.51. Epub 2012 Apr 11.</citation>
    <PMID>22495532</PMID>
  </reference>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 22, 2012</study_first_submitted>
  <study_first_submitted_qc>October 31, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 2, 2012</study_first_posted>
  <last_update_submitted>July 5, 2017</last_update_submitted>
  <last_update_submitted_qc>July 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Diego</investigator_affiliation>
    <investigator_full_name>Richard H. Haas</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Seizures</keyword>
  <keyword>Neonates</keyword>
  <keyword>Anticonvulsants</keyword>
  <keyword>Treatment</keyword>
  <keyword>Levetiracetam</keyword>
  <keyword>Phenobarbital</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Seizures</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etiracetam</mesh_term>
    <mesh_term>Phenobarbital</mesh_term>
    <mesh_term>Piracetam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

